Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy.

marketbeat.com - 2026-07-12 18:02:15

Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growth innovative assets.

fool.com - 2026-07-09 12:12:04

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG tod

gurufocus.com - 2026-07-09 09:00:00

TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics' proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics' proven bios.

businesswire.com - 2026-07-09 08:45:00

Teva secures exclusive global rights to commercialize Polpharma Biologics' biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva's Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.

globenewswire.com - 2026-07-09 08:30:00

In a recent interview, legendary investor Bill Ackman was asked about why he was bullish on the economy of Israel. The question comes with Ackman owning around a 5% stake in the Tel Aviv Stock Exchange.

benzinga.com - 2026-07-08 18:47:32

Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript

seekingalpha.com - 2026-07-07 16:02:42

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

fool.com - 2026-07-06 13:09:01

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

fool.com - 2026-07-03 08:37:20

TEVA is expanding its branded drugs portfolio as Austedo, Ajovy and Uzedy drive higher-margin growth and reshape its business mix.

zacks.com - 2026-06-23 11:01:04

TEVA files an NDA with the FDA seeking approval of ecopipam for the treatment of pediatric Tourette syndrome.

zacks.com - 2026-06-19 10:21:06

The company is seeing higher-margin growth, with EPS rising 72% year over year in the first quarter. The company's yearly guidance disappointed the markets.

fool.com - 2026-06-19 08:36:00

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome.

globenewswire.com - 2026-06-18 16:57:00

TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

globenewswire.com - 2026-06-18 16:30:00

Teva has a handful of new biosimilars on the market, with more to come. Those assets will doubtlessly deliver some top-line growth.

fool.com - 2026-06-12 16:05:00

CHICAGO--(BUSINESS WIRE)--Paragon Biosciences today announced the closing of the sale of Emalex Biosciences to Teva Pharmaceutical, reinforcing Paragon's ability to build innovative biotechnology companies that deliver important treatments to the patients who need them. Emalex is another Paragon Biosciences-founded company built to develop a novel class of treatment for patients with central nervous system disorders, following in the footsteps of other successful Paragon companies such as Harmo.

businesswire.com - 2026-06-11 15:03:00

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva's acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology , and a U.S. NDA submission is anticipated in the second half of 2026.

globenewswire.com - 2026-06-10 12:03:00

Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-08 12:08:31

PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data that highlight the comprehensive tardive dyskinesia (TD) symptom improvement from treatment with AUSTEDO® and AUSTEDO XR®. The new findings, drawn from three separate studies, were presented at Psych Congress Elevate, held June 3 – 6, 2026, in Las Vegas, NV.

globenewswire.com - 2026-06-08 08:00:00

Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.

zacks.com - 2026-06-05 12:50:40

PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life impacts of Huntington's disease (HD) chorea3 and the effect of AUSTEDO® or AUSTEDO XR® on symptom management. The findings demonstrate that treating chorea with AUSTEDO or AUSTEDO XR led to symptom improvement and, as a result, showed improvements across multiple quality of life measures.1 , 2 The data were presented at the Advanced Therapeutics in Movement & Related Disorders® Congress, held June 4 – 8, 2026, in Washington, DC.

globenewswire.com - 2026-06-05 11:30:00

On June 02, 2026, Teva Pharmaceutical Industries Ltd (TEVA) shares fell 4.5% to a current price of $33.08. This decline comes in the context of a 52-week tradin

gurufocus.com - 2026-06-02 18:27:00

PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026. The fireside chat will begin at 8:00 A.M. Eastern Time.

globenewswire.com - 2026-06-01 16:30:00

Thanks to its pivot from generic to branded drug products, Teva Pharmaceutical Industries has experienced a dramatic price rebound. Even after surging 90% higher over the past year, Teva's comeback may have additional runway.

fool.com - 2026-06-01 00:15:00

Teva Pharmaceutical (TEVA) delivered a strong Q1 2026, reinforcing my buy rating and the company's successful pivot to innovative growth assets. TEVA's innovative neuroscience franchise—AUSTEDO, AJOVY, and Uzedy—drove $838M in Q1 revenue, up 41% year over year, offsetting legacy generics decline. Management maintained full-year guidance, with stable gross margins (52.9%) and a clear path to 30% non-GAAP operating income margin by 2027.

seekingalpha.com - 2026-05-25 03:15:00

Teva aims to expand its schizophrenia portfolio after the EMA accepts its filing for olanzapine long-acting injectable (TEV-'749).

zacks.com - 2026-05-22 12:40:27

TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext: MEDCL), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for olanzapine long-acting injectable (TEV-‘749) for the treatment of schizophrenia in adults. TEV-‘749 aims to address treatment adherence in real-world settings and contribute to long-term disease management in people living with schizophrenia.1

globenewswire.com - 2026-05-21 12:30:00

Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.

zacks.com - 2026-05-19 12:26:24

TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency ("Fitch") has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB.

globenewswire.com - 2026-05-18 08:30:00

TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB+.

globenewswire.com - 2026-05-18 08:30:00

PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the ongoing, real-world IMPACT-TD Registry, highlighting a significant gap in diagnosing tardive dyskinesia (TD) in patients with underlying mood disorders. While the findings demonstrate that most patients across all age groups experience multidimensional impact from the condition, young adults (aged 18-29, n=13) had the lowest rate of formal diagnosis (23%) despite having one of the highest rates of personal impact (85%). The data were presented at the 2026 American Psychiatric Association Annual Meeting, taking place May 16 – 20, 2026 in San Francisco, California.

globenewswire.com - 2026-05-18 08:00:00

Teva is pivoting from generic-drug maker to major pharmaceutical company. Even after more than doubling in price over the past year, shares have more room to run, thanks to the company's robust pipeline.

fool.com - 2026-05-15 01:00:00

Teva's turnaround is real -- and may not be over.

fool.com - 2026-05-14 04:56:00

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 15:30:45

PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 12, 2026. The presentation will begin at 9:20 A.M. Pacific Time (12:20 P.M. Eastern Time).

globenewswire.com - 2026-05-04 16:30:00

Teva beats Q1 earnings and revenue estimates as Austedo, Ajovy and Uzedy fuel growth, lifting shares despite weaker generics performance.

zacks.com - 2026-04-30 11:20:31

TEL AVIV, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2025 Healthy Future Report, outlining performance against its sustainability targets, which are focused on the issues most relevant to its business, patients and the planet. Teva surpassed all 2025 targets associated with its sustainability-linked bonds—totaling approximately $7.5 billion across its 2021 and 2023 issuances. These commitments reflect progress in areas such as climate action, health equity and access to medicines, linking financial and sustainability performance.

globenewswire.com - 2026-04-30 08:30:00

A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.

fool.com - 2026-04-30 04:44:00

Teva Pharmaceuticals CEO Richard Francis joins 'Money Movers' to discuss the company's latest acquisition of Emalex Biosciences, their latest drug offerings, and more.

youtube.com - 2026-04-29 14:22:48

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), on Wednesday agreed to acquire Emalex Biosciences, including its lead asset, ecopipam.

benzinga.com - 2026-04-29 13:52:33

While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com - 2026-04-29 12:01:07

Stocks are trading lower as tech and heavy anticipation surrounding today's Fed meeting and Powell speech

schaeffersresearch.com - 2026-04-29 11:57:00

Teva Pharmaceutical Industries ​beat Wall Street ‌estimates for first-quarter profit ​on Wednesday, ​helped by sales ⁠of its ​branded medicines.

reuters.com - 2026-04-29 07:05:54

For an accessible version of this Press Release, please visit www. tevapharm. com Q1 2026 revenues of ~$4. 0 billion increased by 2% in U. S.

globenewswire.com - 2026-04-29 07:00:00

For an accessible version of this Press Release, please visit www.tevapharm.com

globenewswire.com - 2026-04-29 07:00:00

PARSIPPANY, N.J. and CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Emalex Biosciences (“Emalex”) today announced a definitive agreement for Teva to acquire Emalex, including its lead asset, ecopipam. The positive Phase 3 data of ecopipam in children with Tourette syndrome demonstrated statistically significant results on the study's primary efficacy endpoint, and the NDA submission is anticipated in 2H 2026.

globenewswire.com - 2026-04-29 06:30:00

Collectively, analysts tracking the stock expect declines in both revenue and profitability. The company continues to effect a major pivot in its business.

fool.com - 2026-04-27 21:43:00

AE Wealth Management LLC trimmed its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 41.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,027 shares of the company's stock after selling 52,672 shares during the period.

defenseworld.net - 2026-04-21 03:09:01

FDA approval of long-acting schizophrenia drug olanzapine could be Teva's biggest near-term catalyst. Teva's specialty drugs continue to gain momentum.

fool.com - 2026-04-18 04:44:00

PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home Ground™ Schizophrenia Community, a new online platform designed to support people living with schizophrenia and their care partners with community-informed and experienced-based information and support.

globenewswire.com - 2026-04-15 08:00:00